Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Targeting Transient Receptor Potential Melastatin‐2 (TRPM2) Enhances Therapeutic Efficacy of Third Generation EGFR Inhibitors against EGFR Mutant Lung Cancer

Advanced Science(2024)10.1002/advs.202310126Source: DataRank Database

Targeting Transient Receptor Potential Melastatin‐2 (TRPM2) Enhances Therapeutic Efficacy of Third Generation EGFR Inhibitors against EGFR Mutant Lung Cancer is a research paper published in Advanced Science (2024). On theSindex it has a DataRank of 0. It has been cited 10 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access10 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (9 grants)Impact (FWCI 1.88)OA: goldTopics (78)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (10)

Karin A. Vallega ORCID,Vijay K. Boda ORCID,Zihan Quan ORCID,Dongsheng Wang ORCID,Songqing Fan ORCID

Live enrichment

PubMed:39044361 PMC:PMC11425210 OpenAlex:https://openalex.org/W4400963885

National Institutes of Health

Grant: CA233259

National Institutes of Health

Grant: CA148706

National Institutes of Health

Grant: 233220

NCI NIH HHS

Grant: UG1 CA233259

NCI NIH HHS

Grant: R01 CA148706

NCI NIH HHS

Grant: R01 CA223220

National Institutes of Health

Grant: 3UG1CA233259-06S1

ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center

National Institutes of Health

Grant: 5R01CA148706-10

Targeting the colchicine site in tubulin for advanced melanoma

National Institutes of Health

Grant: 5R01CA223220-06

Modulation of death receptor 4 in EGFR-targeted cancer therapy

FWCI

1.88

Citation Percentile

0.8%

Citation Trend

2024

2025

goldLicense: cc-by

journalhttps://doi.org/10.1002/advs.202310126

publisherhttps://doi.org/10.1002/advs.202310126

publisherhttps://advanced.onlinelibrary.wiley.com/doi/pdf/10.1002/advs.202310126

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39044361

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/11425210

Fields of Study

Synthesis and biological activityLung Cancer Treatments and MutationsCancer therapeutics and mechanisms0301 basic medicine03 medical and health sciences0303 health sciencesTRPM Cation ChannelsHumansLung NeoplasmsErbB ReceptorsAcrylamidesCell Line, TumorAniline CompoundsMiceAnimalsProtein Kinase InhibitorsMutationCarcinoma, Non-Small-Cell LungDrug Resistance, NeoplasmApoptosisDisease Models, AnimalIndolesPyrimidines

MeSH Terms

AcrylamidesAniline CompoundsAnimalsCarcinoma, Non-Small-Cell LungDisease Models, AnimalHumansIndolesLung NeoplasmsMutationPyrimidinesApoptosisDrug Resistance, NeoplasmCell Line, TumorProtein Kinase InhibitorsTRPM Cation ChannelsMiceErbB Receptors

Keywords

OsimertinibTransient receptor potential channelCancer researchTRPM2Lung cancerEpidermal growth factor receptorApoptosisTyrosine kinaseCancerPharmacologyMedicineReceptorBiologyErlotinibOncologyInternal medicineBiochemistryCalciumEgfr‐tkisLung NeoplasmsIndolesScienceTRPM Cation ChannelsMiceCell Line, TumorCarcinoma, Non-Small-Cell LungHumansAnimalsProtein Kinase InhibitorsAcrylamidesAniline CompoundsQErbB ReceptorsDisease Models, AnimalPyrimidinesDrug Resistance, NeoplasmMutationResearch Article

Sustainable Development Goals

SDG 0: Good health and well-being